Actively Recruiting
Q702 for the Treatment of Patients With Hematologic Malignancies
Led by Mayo Clinic · Updated on 2025-10-10
46
Participants Needed
2
Research Sites
263 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving Q702 may be safe, tolerable and/or effective in treating patients with hematologic malignancies.
CONDITIONS
Official Title
Q702 for the Treatment of Patients With Hematologic Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Not eligible for or have failed therapies with established benefits as determined by the treating physician
- Relapsed or refractory patients with certain histiocytic diseases without specific gene alterations who have progressed after first-line therapy
- Newly diagnosed patients with Rosai-Dorfman disease without certain gene alterations
- Relapsed or refractory Rosai-Dorfman disease patients with MAPK pathway alteration who failed prior cobimetinib treatment
- Relapsed or refractory Erdheim-Chester disease or Langerhans histiocytosis patients previously treated with vemurafenib or cobimetinib
- Patients with certain histiocytic diseases who cannot tolerate or access BRAF or MEK inhibitors
- Relapsed or refractory higher risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or myelofibrosis with prior treatment failures
- T cell lymphoma or mantle cell lymphoma patients who failed 2 or more therapies
- Primary central nervous system lymphoma patients who failed 2 or more therapies
- Relapsed or refractory follicular lymphoma or Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma patients who failed 2 or more therapies
- Waldenstrom macroglobulinemia patients treated with or ineligible for BTK-inhibitor therapy
- Relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma patients who failed 2 or more therapies including BTK and/or BCL2 inhibitors
- Histopathological or cytological confirmation of disease
- Willingness to provide blood, bone marrow, saliva, and tissue specimens for research
- Ability to swallow pills
- ECOG performance status of 0, 1, or 2
- Life expectancy of 3 months or more
- Measurable or assessable disease as defined for each condition
- Adequate blood counts and organ function within 14 days prior to registration
- Negative pregnancy test for persons of childbearing potential within 7 days prior to registration
- Use of effective contraception during and for 3 months after study participation
- Provide written informed consent
- Ability to complete questionnaires independently or with assistance
- Willingness to return for follow-up visits during active monitoring phase
You will not qualify if you...
- Myeloproliferative neoplasm patients with active central nervous system metastases or carcinomatous meningitis
- Pregnant or nursing persons
- Persons of childbearing potential or able to father a child who do not use adequate contraception
- New York Heart Association Class III or IV cardiac disease or recent serious heart conditions within 6 months
- Corrected QT interval greater than 470 msec
- Active infection with HIV (with low CD4 count or not on therapy), HTLV-1, hepatitis B or C unless controlled
- Active uncontrolled bacterial, viral, or fungal infections requiring systemic therapy
- Use of strong inhibitors or inducers of certain liver enzymes or herbal supplements before and during the study
- Recent use of targeted therapies, monoclonal antibodies, chemotherapy, surgery, investigational therapies, or radiation therapy within specified timeframes
- Failure to recover from acute effects of prior therapy to grade 1 or baseline
- Severe systemic illnesses or other conditions that would interfere with safety assessment
- Active retinal pigment epithelium or photoreceptor disorders, except mild vision issues or single assessable eye without retinopathy
- Active second cancers requiring treatment that would interfere with study assessments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Mayo Clinic in Arizona
Scottsdale, Arizona, United States, 85259
Actively Recruiting
2
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Actively Recruiting
Research Team
C
Clinical Trials Referral Office
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here